Leading Companies in the Global Diabetes Monitoring Devices Market
Author:
Intellectual Market Insights Research
Published Date:
10 Sep 2026
Introduction
For millions of people living with diabetes, the difference between a painful daily finger-stick routine and a painless, continuous stream of glucose data can be transformative reshaping not just how the disease is managed, but how confidently people can live their daily lives. Diabetes monitoring devices, spanning continuous glucose monitors (CGMs), blood glucose meters, and increasingly integrated insulin delivery systems, have moved from niche medical tools to some of the most successful and fastest-adopted medical devices in history.
The global diabetes monitoring devices market was valued at approximately USD 17.54 billion in 2025 and is projected to reach USD 34.49 billion by 2034, expanding at a compound annual growth rate (CAGR) of 7.8% over the forecast period. Growth is being driven by rising global diabetes prevalence, rapid adoption of continuous glucose monitoring technology, expanding insurance reimbursement, and the growing integration of monitoring devices with automated insulin delivery systems.
The competitive landscape is led by a small group of medical device companies that have built deep expertise in biosensor technology, wireless connectivity, and regulatory navigation across major healthcare markets. Because glucose monitoring devices must combine clinical-grade accuracy with consumer-friendly usability, the market rewards companies that can pair rigorous engineering with the manufacturing scale, app ecosystems, and payer relationships needed to reach the more than 500 million people worldwide living with diabetes.
Understanding which companies lead this rapidly evolving market is essential for healthcare providers, payers, and patients navigating an increasingly crowded field of monitoring technology. This article provides a research-based analysis of the top companies in the global diabetes monitoring devices market, their positioning, flagship offerings, and the technological forces shaping the competitive landscape.
Market Overview
|
Parameter |
Details |
|---|---|
|
Market Size (2025) |
USD 17.54 Billion |
|
Projected Market Size (2034) |
USD 34.49 Billion |
|
CAGR (2025–2034) |
7.8% |
|
Key Growth Drivers |
Rising global diabetes prevalence, rapid CGM adoption, integration with automated insulin delivery systems |
|
Key Challenges |
High device and sensor costs, reimbursement and access disparities across regions |
|
Key Opportunities |
Over-the-counter CGM expansion, integration with AI-driven analytics, growth in emerging markets |
Why the Diabetes Monitoring Devices Market Is Growing
1. Rising Global Diabetes Prevalence
With more than 500 million people worldwide living with diabetes and only a small fraction currently using continuous glucose monitors, the addressable population for monitoring devices remains enormous and continues to expand as diabetes rates rise globally.
2. Rapid Adoption of Continuous Glucose Monitoring
CGM systems are increasingly replacing traditional fingerstick testing by offering real-time glucose data without painful, repetitive blood draws, driving strong double-digit growth for leading CGM manufacturers in recent years.
3. Expansion into Over-the-Counter and Type 2 Markets
Regulatory approvals for over-the-counter CGM systems are opening the technology to a much broader population beyond insulin-dependent patients, including people with type 2 diabetes and even non-diabetic wellness users.
4. Integration with Automated Insulin Delivery Systems
Growing integration between CGMs and automated insulin pumps is creating closed-loop systems that automatically adjust insulin delivery based on real-time glucose readings, increasing the value proposition of monitoring devices as part of a broader diabetes management ecosystem.
5. Expanding Insurance Reimbursement
Broader reimbursement coverage for CGM systems across the U.S., Europe, and other developed markets is lowering the cost barrier for patients and driving faster adoption among both type 1 and type 2 diabetes populations.
6. Growth in Digital Health and Data Connectivity
Companion apps and cloud-based data platforms are enhancing the value of monitoring devices by giving patients and healthcare providers actionable insights into glucose trends, supporting more informed treatment decisions.
Top Companies in the Global Diabetes Monitoring Devices Market
- Abbott Diabetes Care
- Dexcom
- Medtronic (MiniMed / Diabetes)
- Insulet Corporation
- Roche Diabetes Care
- Embecta
- Ascensia Diabetes Care
- LifeScan
- AgaMatrix
1. Abbott Diabetes Care
|
Category |
Details |
|---|---|
|
Company Name |
Abbott Diabetes Care (division of Abbott Laboratories) |
|
Headquarters |
Alameda, California, United States (parent Abbott headquartered in Illinois) |
|
Founded |
Abbott Laboratories founded 1888; Diabetes Care built around the FreeStyle Libre franchise |
|
Employees |
Diabetes Care is part of Abbott's roughly 114,000+ global workforce |
|
Revenue |
Approx. USD 6.8+ Billion in Diabetes Care revenue (FY2024, largely CGM sales), with continued double-digit growth into 2025 |
|
Company Overview |
Abbott Diabetes Care is the division behind FreeStyle Libre, described by the company as the most successful medical device of all time, now used by roughly 7 million people worldwide for continuous glucose monitoring. |
|
Key Products |
FreeStyle Libre 2 and Libre 3 CGM systems, plus newer over-the-counter offerings Lingo and Libre Rio, built on the same core sensor technology. |
|
Market Position |
The global CGM volume leader, with Abbott targeting USD 10 billion in annual Diabetes Care sales by 2028 as it continues to expand access among the roughly 490 million people with diabetes not yet using a CGM. |
|
Recent Developments |
Received FDA approval for two new over-the-counter CGM systems, Lingo and Libre Rio, marking the start of a new era of consumer-accessible glucose monitoring in the United States. |
|
Strategic Advantages |
Massive existing user base and brand recognition, continued double-digit organic growth, and a broadening product line spanning prescription and consumer wellness use cases. |
2. Dexcom
|
Category |
Details |
|---|---|
|
Company Name |
DexCom, Inc. |
|
Headquarters |
San Diego, California, United States |
|
Founded |
1999 |
|
Employees |
Approx. 9,000–11,100 |
|
Revenue |
Approx. USD 4.66 Billion (FY2025) |
|
Company Overview |
Dexcom is a pure-play continuous glucose monitoring company that has built its business entirely around CGM technology, offering an integrated suite of apps and data platforms alongside its sensor hardware for people with diabetes and their care teams. |
|
Key Products |
Dexcom G7 CGM system, the Stelo over-the-counter glucose biosensor, and the Clarity data management and analytics platform. |
|
Market Position |
One of the three leading CGM makers by volume in the U.S. alongside Abbott and Medtronic, with 2025 revenue growth driven by continued sensor volume growth, Stelo's rollout, and international expansion. |
|
Recent Developments |
Underwent a leadership transition with COO Jake Leach succeeding Kevin Sayer as CEO effective January 2026, while continuing the rollout of a 15-day version of its G7 monitor and pursuing a broader restructuring to streamline operations. |
|
Strategic Advantages |
Singular focus on CGM technology and data platforms, deep integration partnerships with insulin pump makers including Insulet, and continued international expansion supporting sustained double-digit growth. |
3. Insulet Corporation
|
Category |
Details |
|---|---|
|
Company Name |
Insulet Corporation |
|
Headquarters |
Acton, Massachusetts, United States |
|
Founded |
2000 |
|
Employees |
Approx. 5,000–5,400 |
|
Revenue |
Approx. USD 2.7–2.9 Billion (FY2025) |
|
Company Overview |
Insulet is the global leader in tubeless insulin pump technology through its Omnipod brand, offering an automated insulin delivery system that integrates with CGM sensors from partners including Dexcom and Abbott to manage blood glucose without multiple daily injections. |
|
Key Products |
Omnipod 5 Automated Insulin Delivery System, compatible with Dexcom's G7 CGM and Abbott's FreeStyle Libre 2 Plus and Libre 3 Plus sensors. |
|
Market Position |
The global leader in tubeless insulin pump technology, posting its tenth consecutive year of 20%-or-greater constant-currency revenue growth in fiscal 2025, with strong momentum in both U.S. and international markets. |
|
Recent Developments |
Launched the Omnipod 5 App for iPhone compatible with Dexcom's G7 CGM sensor, and expanded international integrations with both Dexcom and Abbott CGM sensors across multiple countries. |
|
Strategic Advantages |
Differentiated tubeless pump design, deep multi-vendor CGM integration partnerships, and a track record of sustained high double-digit revenue growth across a decade. |
4. Medtronic Diabetes / MiniMed
|
Category |
Details |
|---|---|
|
Company Name |
Medtronic Diabetes, being spun off as MiniMed Group, Inc. |
|
Headquarters |
Northridge, California, United States |
|
Founded |
Medtronic Diabetes business built over several decades within Medtronic plc |
|
Employees |
More than 8,000 dedicated to the Diabetes business |
|
Revenue |
Approx. USD 2.76 Billion (FY2025, up 10.7% year-over-year) |
|
Company Overview |
Medtronic's Diabetes Operating Unit develops technologies and therapies for type 1 and type 2 diabetes management, including automated insulin delivery systems, and is in the process of separating into an independent, publicly traded company called MiniMed Group. |
|
Key Products |
MiniMed 780G automated insulin delivery system, with FDA approval received to broaden the system's compatibility and patient eligibility. |
|
Market Position |
One of the top three CGM and insulin delivery market leaders by volume in the U.S. alongside Abbott and Dexcom, with diabetes representing a fast-growing but historically smaller segment of Medtronic's broader medical device portfolio. |
|
Recent Developments |
Medtronic announced the planned separation of its Diabetes business into an independent, standalone public company (MiniMed Group), pursuing an IPO valuing the new company at approximately USD 7.86 billion. |
|
Strategic Advantages |
Decades of insulin pump and closed-loop system engineering experience, dedicated manufacturing scale, and a pending independent corporate structure expected to enable more focused investment in automated insulin delivery innovation. |
5. Roche Diabetes Care
|
Category |
Details |
|---|---|
|
Company Name |
Roche Diabetes Care (division of Roche Holding AG) |
|
Headquarters |
Indianapolis, Indiana, United States (parent Roche headquartered in Basel, Switzerland) |
|
Founded |
Nearly 50 years of experience in diabetes care as part of Roche, a company founded in 1896 |
|
Employees |
Approx. 4,500 across more than 100 countries |
|
Revenue |
Part of Roche's broader Diagnostics division within a group generating CHF 62.39 Billion in total revenue (2024) |
|
Company Overview |
Roche Diabetes Care offers one of the most comprehensive portfolios of diabetes management products and services globally under its Accu-Chek and mySugr brands, spanning blood glucose meters, insulin delivery systems, and digital diabetes management tools. |
|
Key Products |
Accu-Chek blood glucose meters and insulin pump systems including Accu-Chek Solo, and the mySugr mobile app for diabetes self-monitoring and data tracking. |
|
Market Position |
A long-established global leader in blood glucose monitoring, leveraging well-established relationships with healthcare professionals, governments, and institutions across more than 100 countries. |
|
Recent Developments |
Continues to expand its digital diabetes management ecosystem by integrating the mySugr app with its Accu-Chek hardware portfolio, supporting more connected, data-driven diabetes care. |
|
Strategic Advantages |
Nearly five decades of diabetes-specific expertise, deep global distribution and healthcare-system relationships, and the backing of one of the world's largest diagnostics and pharmaceutical companies. |
Competitive Landscape
The global diabetes monitoring devices market is led by a concentrated group of companies, with Abbott, Dexcom, and Medtronic representing the top three CGM and insulin-delivery market leaders by volume in the U.S., while Insulet leads in tubeless insulin pump technology and Roche Diabetes Care maintains a long-established global presence in blood glucose meters.
Sensor Accuracy and Regulatory Approval as a Barrier to Entry: Continuous glucose monitoring requires clinical-grade sensor accuracy validated through rigorous regulatory review, favoring established players like Abbott and Dexcom with decades of biosensor engineering and regulatory experience.
Ecosystem Integration as a Competitive Differentiator: Companies increasingly compete not just on standalone devices but on how well their systems integrate with partner technologies, as seen in Insulet's Omnipod 5 integrations with both Dexcom and Abbott CGM sensors.
Corporate Restructuring to Sharpen Focus: Medtronic's planned spin-off of its Diabetes business into an independent company, MiniMed Group, reflects a broader industry pattern of diabetes-focused divisions seeking more focused investment and faster decision-making outside larger diversified parent companies.
Expansion Beyond Insulin-Dependent Patients: Companies like Abbott are competing to capture a much larger addressable market by launching over-the-counter CGM products aimed at type 2 diabetes patients and wellness-focused consumers who don't require a prescription.
Emerging Trends in the Diabetes Monitoring Devices Market
1. Over-the-Counter CGM Expansion: Regulatory approval of consumer-accessible CGM products, such as Abbott's Lingo and Libre Rio and Dexcom's Stelo, is opening glucose monitoring to a much broader population beyond insulin-dependent patients.
2. Closed-Loop Automated Insulin Delivery: Deepening integration between CGM sensors and insulin pumps is enabling increasingly automated, closed-loop systems that adjust insulin delivery in real time based on continuous glucose readings.
3. Corporate Restructuring and Spin-Offs: Diabetes-focused divisions within larger diversified medical device companies, such as Medtronic's Diabetes unit and BD's earlier diabetes unit spin-off as Embecta, are increasingly being separated into independent, more focused companies.
4. Multi-Vendor Interoperability: Insulin pump makers are increasingly building compatibility with CGM sensors from multiple manufacturers rather than relying on a single proprietary sensor partner, giving patients more choice in assembling their diabetes management systems.
5. Digital Health and Data Analytics Integration: Companion apps and cloud-based platforms like Roche's mySugr and Dexcom's Clarity are becoming central to the value proposition of monitoring devices, turning raw glucose data into actionable insights for patients and care teams.
Future Outlook (2025–2034)
The global diabetes monitoring devices market's trajectory toward USD 34.49 billion by 2034 reflects the technology's continued shift from a niche prescription tool to a mainstream consumer health product, supported by rising diabetes prevalence and expanding insurance coverage. The 7.8% CAGR forecast through 2034 assumes continued double-digit CGM sensor volume growth, deepening integration with automated insulin delivery, and continued expansion into over-the-counter and type 2 diabetes populations.
Key investment themes include continued growth in over-the-counter glucose monitoring, deepening multi-vendor interoperability between CGMs and insulin pumps, and corporate restructuring that sharpens strategic focus within diabetes-specific business units. Leading companies including Abbott Diabetes Care, Dexcom, Insulet, and the soon-to-be-independent MiniMed Group are likely to retain strong market positions by combining sensor accuracy and manufacturing scale with expanding digital health ecosystems, while established players like Roche Diabetes Care continue to compete on long-standing global distribution relationships.
Frequently Asked Questions (FAQ)
1. What is the current size of the global diabetes monitoring devices market?
The global diabetes monitoring devices market was valued at approximately USD 17.54 billion in 2025 and is projected to reach USD 34.49 billion by 2034, growing at a CAGR of 7.8%.
2. Who are the top companies in the diabetes monitoring devices market?
Leading companies include Abbott Diabetes Care, Dexcom, Medtronic (spinning off as MiniMed Group), Insulet Corporation, Roche Diabetes Care, Embecta, Ascensia Diabetes Care, LifeScan, and AgaMatrix.
3. What is the forecast CAGR for the diabetes monitoring devices market?
The market is forecast to grow at a CAGR of 7.8% from 2025 to 2034.
4. What are the main growth drivers for this market?
Key drivers include rising global diabetes prevalence, rapid continuous glucose monitor adoption, and growing integration between CGMs and automated insulin delivery systems.
5. Which segment is driving the most growth in this market?
Continuous glucose monitoring is the fastest-growing segment, with leading manufacturers posting sustained double-digit revenue growth as adoption expands beyond insulin-dependent patients into broader type 2 diabetes and wellness markets.
6. Why is Medtronic spinning off its diabetes business?
Medtronic announced plans to separate its Diabetes business into an independent public company, MiniMed Group, to enable more focused investment in automated insulin delivery innovation and give the unit a shareholder base better aligned with its specific business profile.
7. What role do companion apps play in diabetes monitoring?
Companion apps like Dexcom's Clarity and Roche's mySugr have become central to the value of modern monitoring devices, turning raw sensor data into actionable insights that help patients and healthcare providers make more informed treatment decisions.
Conclusion
The global diabetes monitoring devices market sits at the intersection of medical necessity and rapid consumer technology adoption, transforming how hundreds of millions of people manage a chronic condition. With a projected size of USD 34.49 billion by 2034 at a 7.8% CAGR, the sector offers strong growth potential for companies that can combine clinical-grade sensor accuracy with the ecosystem integration and consumer accessibility that today's patients expect.
Abbott and Dexcom continue to lead on CGM volume and innovation, Insulet has built a differentiated position in tubeless automated insulin delivery, and Medtronic's planned spin-off into MiniMed Group signals a broader industry shift toward more focused, independently resourced diabetes technology businesses. The companies that successfully expand into over-the-counter use cases, deepen multi-vendor interoperability, and strengthen digital health platforms will define market leadership through 2034 and beyond.
